FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound of formula (II)
(II)
or a pharmaceutically acceptable salt thereof, in which Q denotes pyridinyl, R1 is selected from piperazinyl and piperidinyl, which is substituted with at least one substitute, such as one, two, three or four substituents independently selected from RX, R2 denotes C3-10 cycloalkyl, R3 is selected from hydrogen and C1-6 alkyl, R4 is selected from hydrogen and C1-6 alkyl, R5 is independently selected from hydrogen and halogen, each RX is independently selected from piperazinyl, piperidinyl and morpholinyl, which is unsubstituted or substituted with at least one substitute, such as one, two, three or four substituents, independently selected from RY, each RY is independently selected from halogen, CN and C1-6 alkyl, m is selected from 0, 1, 2 and 3, which are inhibitors of CDK4/6 kinase activity and can be used for treating hyperproliferative diseases, such as cancer and inflammation.
EFFECT: some inhibitors of protein kinase are proposed.
15 cl, 4 tbl, 8 ex
Title | Year | Author | Number |
---|---|---|---|
CERTAIN PROTEIN KINASE INHIBITORS | 2015 |
|
RU2671494C2 |
INHIBITOR OF CERTAIN PROTEIN KINASES | 2016 |
|
RU2732952C2 |
APOPTOSIS-INDUCING AGENTS | 2018 |
|
RU2782469C2 |
ALK KINASE INHIBITORS | 2013 |
|
RU2675850C2 |
BENZIMIDAZOLE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND USE | 2017 |
|
RU2779534C2 |
SUBSTITUTED PYRROLO [2,3-D] PYRIDAZIN-4-ONES AND PYRAZOLO [3,4-D] PYRIDAZIN-4-ONES AS PROTEINKINASE INHIBITORS | 2017 |
|
RU2749038C2 |
SUBSTITUTED (2-AZABICYCLO[3.1.0]HEXANE-2-YL)PYRAZOLO[1.5-A]PYRIMIDINE AND IMIDAZO[1.2-B]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS | 2019 |
|
RU2781618C2 |
MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | 2019 |
|
RU2778294C2 |
REGULATORS OF DERIVATIVES OF STEROIDS, METHODS OF THEIR OBTAINING AND USE | 2019 |
|
RU2803499C1 |
PHARMACEUTICAL COMBINATION CONTAINING TNO155 AND RIBOCICLIB | 2020 |
|
RU2813111C2 |
Authors
Dates
2020-12-17—Published
2017-05-05—Filed